Last reviewed · How we verify
placebo po
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, without active pharmacological ingredients.
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, without active pharmacological ingredients. Used for Symptom management in clinical trial control arms, Conditions responsive to expectation effects (pain, nausea, fatigue).
At a glance
| Generic name | placebo po |
|---|---|
| Also known as | tablet containing microcrystalline cellulose, Oral Placebo Pill, Baxter sterile water |
| Sponsor | St. Justine's Hospital |
| Modality | Small molecule |
| Therapeutic area | Multiple (symptom management) |
| Phase | FDA-approved |
Mechanism of action
Placebo works via psychological and neurobiological mechanisms including expectation, conditioning, and activation of endogenous pain-relief and reward pathways. The effect is particularly pronounced in conditions with subjective symptom components such as pain, nausea, and fatigue. While placebo has no direct molecular target, clinical benefit can occur through mind-body interactions and regression to the mean.
Approved indications
- Symptom management in clinical trial control arms
- Conditions responsive to expectation effects (pain, nausea, fatigue)
Common side effects
- Nocebo effects (adverse events attributed to placebo)
Key clinical trials
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (PHASE3)
- Testing Obeticholic Acid for Familial Adenomatous Polyposis (PHASE2)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo po CI brief — competitive landscape report
- placebo po updates RSS · CI watch RSS
- St. Justine's Hospital portfolio CI